Literature DB >> 19808264

The tumultuous journey of nesiritide: past, present, and future.

John C Burnett, Josef Korinek.   

Abstract

Mesh：

Substances：

Year:  2008        PMID： 19808264      PMCID： PMC4684180          DOI： 10.1161/CIRCHEARTFAILURE.108.776294

Source DB:  PubMed          Journal:  Circ Heart Fail        ISSN： 1941-3289            Impact factor:   8.790


× No keyword cloud information.
  30 in total

1.  Nonhypotensive low-dose nesiritide has differential renal effects compared with standard-dose nesiritide in patients with acute decompensated heart failure and renal dysfunction.

Authors:  Henry G Riter; Margaret M Redfield; John C Burnett; Horng H Chen
Journal:  J Am Coll Cardiol       Date:  2006-05-16       Impact factor: 24.094

2.  Effect of nesiritide (B-type natriuretic peptide) and dobutamine on ventricular arrhythmias in the treatment of patients with acutely decompensated congestive heart failure: the PRECEDENT study.

Authors:  Andrew J Burger; Darlene P Horton; Thierry LeJemtel; Jalal K Ghali; Guillermo Torre; George Dennish; Michael Koren; Jay Dinerman; Marc Silver; Mei L Cheng; Uri Elkayam
Journal:  Am Heart J       Date:  2002-12       Impact factor: 4.749

3.  Immunoreactivity and guanosine 3',5'-cyclic monophosphate activating actions of various molecular forms of human B-type natriuretic peptide.

Authors:  Denise M Heublein; Brenda K Huntley; Guido Boerrigter; Alessandro Cataliotti; Sharon M Sandberg; Margaret M Redfield; John C Burnett
Journal:  Hypertension       Date:  2007-03-19       Impact factor: 10.190

4.  Cardiac phosphodiesterase 5 (cGMP-specific) modulates beta-adrenergic signaling in vivo and is down-regulated in heart failure.

Authors:  H Senzaki; C J Smith; G J Juang; T Isoda; S P Mayer; A Ohler; N Paolocci; G F Tomaselli; J M Hare; D A Kass
Journal:  FASEB J       Date:  2001-08       Impact factor: 5.191

5.  Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure. Nesiritide Study Group.

Authors:  W S Colucci; U Elkayam; D P Horton; W T Abraham; R C Bourge; A D Johnson; L E Wagoner; M M Givertz; C S Liang; M Neibaur; W H Haught; T H LeJemtel
Journal:  N Engl J Med       Date:  2000-07-27       Impact factor: 91.245

6.  Effect of nesiritide versus dobutamine on short-term outcomes in the treatment of patients with acutely decompensated heart failure.

Authors:  Marc A Silver; Darlene P Horton; Jalal K Ghali; Uri Elkayam
Journal:  J Am Coll Cardiol       Date:  2002-03-06       Impact factor: 24.094

7.  Safety and feasibility of using serial infusions of nesiritide for heart failure in an outpatient setting (from the FUSION I trial).

Authors:  Clyde W Yancy; Mitchell T Saltzberg; Robert L Berkowitz; Barry Bertolet; Krishnaswami Vijayaraghavan; Kenneth Burnham; Ron M Oren; Kirk Walker; Darlene P Horton; Marc A Silver
Journal:  Am J Cardiol       Date:  2004-09-01       Impact factor: 2.778

8.  Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.

Authors:  M Yoshimura; H Yasue; E Morita; N Sakaino; M Jougasaki; M Kurose; M Mukoyama; Y Saito; K Nakao; H Imura
Journal:  Circulation       Date:  1991-10       Impact factor: 29.690

9.  The safety of intravenous diuretics alone versus diuretics plus parenteral vasoactive therapies in hospitalized patients with acutely decompensated heart failure: a propensity score and instrumental variable analysis using the Acutely Decompensated Heart Failure National Registry (ADHERE) database.

Authors:  Maria Rosa Costanzo; R S Johannes; Michael Pine; Vikas Gupta; Mitchell Saltzberg; Joel Hay; Clyde W Yancy; Gregg C Fonarow
Journal:  Am Heart J       Date:  2007-08       Impact factor: 4.749

10.  Evidence for functional heterogeneity of circulating B-type natriuretic peptide.

Authors:  Faquan Liang; Jessica O'Rear; Ute Schellenberger; Lungkuo Tai; Michael Lasecki; George F Schreiner; Fred S Apple; Alan S Maisel; N Stephen Pollitt; Andrew A Protter
Journal:  J Am Coll Cardiol       Date:  2007-02-26       Impact factor: 24.094
View more
  9 in total

Review 1.  Nesiritide in acute decompensated heart failure: current status and future perspectives.

Authors:  Selma F Mohammed; Josef Korinek; Horng H Chen; John C Burnett; Margaret M Redfield
Journal:  Rev Cardiovasc Med       Date:  2008       Impact factor: 2.930

2.  Impaired sinoatrial node function and increased susceptibility to atrial fibrillation in mice lacking natriuretic peptide receptor C.

Authors:  Emmanuel E Egom; Kimberly Vella; Rui Hua; Hailey J Jansen; Motahareh Moghtadaei; Iuliia Polina; Oleg Bogachev; Rhea Hurnik; Martin Mackasey; Sara Rafferty; Gibanananda Ray; Robert A Rose
Journal:  J Physiol       Date:  2015-01-12       Impact factor: 5.182

Review 3.  CD-NP: an innovative designer natriuretic peptide activator of particulate guanylyl cyclase receptors for cardiorenal disease.

Authors:  Paul M McKie; S Jeson Sangaralingham; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2010-09

Review 4.  Advances in the epidemiology of heart failure and left ventricular remodeling.

Authors:  Susan Cheng; Ramachandran S Vasan
Journal:  Circulation       Date:  2011-11-15       Impact factor: 29.690

Review 5.  Insights into natriuretic peptides in heart failure: an update.

Authors:  Josef Korinek; Guido Boerrigter; Selma F Mohammed; John C Burnett
Journal:  Curr Heart Fail Rep       Date:  2008-06

Review 6.  Modulation of cGMP in heart failure: a new therapeutic paradigm.

Authors:  Guido Boerrigter; Harald Lapp; John C Burnett
Journal:  Handb Exp Pharmacol       Date:  2009

7.  Pharmacodynamics of a novel designer natriuretic peptide, CD-NP, in a first-in-human clinical trial in healthy subjects.

Authors:  Candace Y W Lee; Horng H Chen; Ondrej Lisy; Suzanne Swan; Courtney Cannon; Hsiao D Lieu; John C Burnett
Journal:  J Clin Pharmacol       Date:  2009-04-24       Impact factor: 3.126

8.  Rationale and design of a randomized, double-blind, placebo-controlled clinical trial to evaluate the efficacy of B-type natriuretic peptide for the preservation of left ventricular function after anterior myocardial infarction.

Authors:  S Jeson Sangaralingham; John C Burnett; Paul M McKie; John A Schirger; Horng H Chen
Journal:  J Card Fail       Date:  2013-08       Impact factor: 5.712

Review 9.  Designer natriuretic peptides.

Authors:  Candace Y W Lee; Hsiao Lieu; John C Burnett
Journal:  J Investig Med       Date:  2009-01       Impact factor: 2.895
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.